2 Stocks Soaring on Positive Drug Data

Options traders have been call-heavy on Merck stock over the past two weeks

Managing Editor
Apr 9, 2018 at 9:52 AM
facebook X logo linkedin

Shares of pharmaceutical concerns Merck & Co., Inc. (NYSE:MRK) and Verastem Inc (NASDAQ:VSTM) are soaring in early trading, after reporting positive drug data. Below, we'll dig deeper into how MRK and VSTM stocks have been faring on the charts.

Keytruda Results Send MRK Higher

Merck stock is surging after the company's Keytruda drug met its main goal in a late-stage lung cancer trial. More specifically, the drug met its goal of helping previously untreated patients live longer. In response, MRK stock was up 2.7% at $54.81, at last check. 

From a longer-term perspective, shares of MRK have been struggling in 2018, touching a two-year low of $52.83 just last Tuesday. The security has shed close to 17% over the past six months, and has yet to recover from an October bear gap suffered after Merck pulled its European marketing application for Keytruda.

Despite its technical shortcomings, options traders have been more bullish than usual towards MRK of late. Data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) shows Merck stock with a 10-day call/put volume ratio of 5.32, ranking in the 90th percentile of its annual range. This suggests calls have been purchased over puts at a much faster-than-usual clip over the past two weeks.

Analyst sentiment has also remained optimistic. Of the 12 brokerage firms following MRK, eight currently sport "strong buy" recommendations.

VSTM Receives an FDA Lift

Verstem stock was last seen trading 12.5% higher at $3.33, after the Food & Drug Administration (FDA) accepted a new drug application (NDA) and granted "priority review" status for the biotech's chronic lymphocytic leukemia and lymphoma drug, duvelisib.

Still, VSTM stock has shed 36% over the past six months, and last week touched a 10-month low of $2.77. Nevertheless, analysts have remained bullish. VSTM currently sports an average 12-month price target of $12.67, which represents a whopping 277% premium to current levels, and all six brokerage firms following the stock carry "buy" or "strong buy" ratings.

Currently, the drug concern's Schaeffer's Volatility Index (SVI) sits at 155%. While that might seem high, this reading actually ranks in the low 8th percentile of its annual range, indicating Verastem's near-term options are pricing in relatively muted volatility expectations right now.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI